Antibiotic resistance is one of the defining medical crises of this century, and a precise understanding of how resistance enzymes work at the atomic level is essential for designing drugs that can overcome them. A structural insight published in PNAS illuminates a previously inaccessible layer of detail in the mechanism by which β-lactamase enzymes neutralize antibiotics — and how a clinical inhibitor like avibactam disrupts that process.
The study applied an accelerated NMR crystallography workflow to the Toho-1 β-lactamase enzyme bound to avibactam, a non-β-lactam inhibitor used clinically in combination with ceftazidime. By integrating solid-state NMR with X-ray crystallography, the team mapped the protonation states of key residues within the enzyme's active site — information that conventional crystallography cannot resolve because X-rays cannot reliably locate hydrogen atoms. Protonation states determine whether a chemical group acts as an acid or base, directly governing enzyme catalysis. The resulting atomic-resolution picture clarifies precisely how avibactam engages the enzyme and why it functions as an effective inhibitor.
This finding sits at the intersection of structural biology and medicinal chemistry, an area where incremental mechanistic clarity can translate into meaningful drug design advances. β-lactamases represent the primary resistance mechanism against penicillins, cephalosporins, and carbapenems, and understanding how inhibitors like avibactam achieve their effect at the proton level has been a longstanding gap. The NMR crystallography approach itself may prove to be the more durable contribution here: if this accelerated workflow becomes broadly adopted, it could systematically close a blind spot in structure-based drug discovery across many enzyme targets. The limitation is that this remains highly specialized structural work — compelling mechanistically, but not yet linked to clinical outcomes or new inhibitor designs. Its value to human health is upstream and indirect, contingent on the insights being leveraged in future drug development campaigns.